Cargando…

Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation

BACKGROUND: We have previously reported significant downregulation of ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) in prostate cancer (PCa) compared to the surrounding benign tissue. UCHL1 plays an important role in ubiquitin system and different cellular processes such as cell proliferation and...

Descripción completa

Detalles Bibliográficos
Autores principales: Ummanni, Ramesh, Jost, Edgar, Braig, Melanie, Lohmann, Frithjof, Mundt, Frederike, Barett, Christine, Schlomm, Thorsten, Sauter, Guido, Senff, Tina, Bokemeyer, Carsten, Sültmann, Holger, Meyer-Schwesinger, Catherine, Brümmendorf, Tim H, Balabanov, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3212821/
https://www.ncbi.nlm.nih.gov/pubmed/21999842
http://dx.doi.org/10.1186/1476-4598-10-129
_version_ 1782216030824693760
author Ummanni, Ramesh
Jost, Edgar
Braig, Melanie
Lohmann, Frithjof
Mundt, Frederike
Barett, Christine
Schlomm, Thorsten
Sauter, Guido
Senff, Tina
Bokemeyer, Carsten
Sültmann, Holger
Meyer-Schwesinger, Catherine
Brümmendorf, Tim H
Balabanov, Stefan
author_facet Ummanni, Ramesh
Jost, Edgar
Braig, Melanie
Lohmann, Frithjof
Mundt, Frederike
Barett, Christine
Schlomm, Thorsten
Sauter, Guido
Senff, Tina
Bokemeyer, Carsten
Sültmann, Holger
Meyer-Schwesinger, Catherine
Brümmendorf, Tim H
Balabanov, Stefan
author_sort Ummanni, Ramesh
collection PubMed
description BACKGROUND: We have previously reported significant downregulation of ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) in prostate cancer (PCa) compared to the surrounding benign tissue. UCHL1 plays an important role in ubiquitin system and different cellular processes such as cell proliferation and differentiation. We now show that the underlying mechanism of UCHL1 downregulation in PCa is linked to its promoter hypermethylation. Furthermore, we present evidences that UCHL1 expression can affect the behavior of prostate cancer cells in different ways. RESULTS: Methylation specific PCR analysis results showed a highly methylated promoter region for UCHL1 in 90% (18/20) of tumor tissue compared to 15% (3/20) of normal tissues from PCa patients. Pyrosequencing results confirmed a mean methylation of 41.4% in PCa whereas only 8.6% in normal tissues. To conduct functional analysis of UCHL1 in PCa, UCHL1 is overexpressed in LNCaP cells whose UCHL1 expression is normally suppressed by promoter methylation and found that UCHL1 has the ability to decrease the rate of cell proliferation and suppresses anchorage-independent growth of these cells. In further analysis, we found evidence that exogenous expression of UCHL1 suppress LNCaP cells growth probably via p53-mediated inhibition of Akt/PKB phosphorylation and also via accumulation of p27kip1 a cyclin dependant kinase inhibitor of cell cycle regulating proteins. Notably, we also observed that exogenous expression of UCHL1 induced a senescent phenotype that was detected by using the SA-ß-gal assay and might be due to increased p14ARF, p53, p27kip1 and decreased MDM2. CONCLUSION: From these results, we propose that UCHL1 downregulation via promoter hypermethylation plays an important role in various molecular aspects of PCa biology, such as morphological diversification and regulation of proliferation.
format Online
Article
Text
id pubmed-3212821
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32128212011-11-11 Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation Ummanni, Ramesh Jost, Edgar Braig, Melanie Lohmann, Frithjof Mundt, Frederike Barett, Christine Schlomm, Thorsten Sauter, Guido Senff, Tina Bokemeyer, Carsten Sültmann, Holger Meyer-Schwesinger, Catherine Brümmendorf, Tim H Balabanov, Stefan Mol Cancer Research BACKGROUND: We have previously reported significant downregulation of ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) in prostate cancer (PCa) compared to the surrounding benign tissue. UCHL1 plays an important role in ubiquitin system and different cellular processes such as cell proliferation and differentiation. We now show that the underlying mechanism of UCHL1 downregulation in PCa is linked to its promoter hypermethylation. Furthermore, we present evidences that UCHL1 expression can affect the behavior of prostate cancer cells in different ways. RESULTS: Methylation specific PCR analysis results showed a highly methylated promoter region for UCHL1 in 90% (18/20) of tumor tissue compared to 15% (3/20) of normal tissues from PCa patients. Pyrosequencing results confirmed a mean methylation of 41.4% in PCa whereas only 8.6% in normal tissues. To conduct functional analysis of UCHL1 in PCa, UCHL1 is overexpressed in LNCaP cells whose UCHL1 expression is normally suppressed by promoter methylation and found that UCHL1 has the ability to decrease the rate of cell proliferation and suppresses anchorage-independent growth of these cells. In further analysis, we found evidence that exogenous expression of UCHL1 suppress LNCaP cells growth probably via p53-mediated inhibition of Akt/PKB phosphorylation and also via accumulation of p27kip1 a cyclin dependant kinase inhibitor of cell cycle regulating proteins. Notably, we also observed that exogenous expression of UCHL1 induced a senescent phenotype that was detected by using the SA-ß-gal assay and might be due to increased p14ARF, p53, p27kip1 and decreased MDM2. CONCLUSION: From these results, we propose that UCHL1 downregulation via promoter hypermethylation plays an important role in various molecular aspects of PCa biology, such as morphological diversification and regulation of proliferation. BioMed Central 2011-10-14 /pmc/articles/PMC3212821/ /pubmed/21999842 http://dx.doi.org/10.1186/1476-4598-10-129 Text en Copyright ©2011 Ummanni et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Ummanni, Ramesh
Jost, Edgar
Braig, Melanie
Lohmann, Frithjof
Mundt, Frederike
Barett, Christine
Schlomm, Thorsten
Sauter, Guido
Senff, Tina
Bokemeyer, Carsten
Sültmann, Holger
Meyer-Schwesinger, Catherine
Brümmendorf, Tim H
Balabanov, Stefan
Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation
title Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation
title_full Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation
title_fullStr Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation
title_full_unstemmed Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation
title_short Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation
title_sort ubiquitin carboxyl-terminal hydrolase 1 (uchl1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3212821/
https://www.ncbi.nlm.nih.gov/pubmed/21999842
http://dx.doi.org/10.1186/1476-4598-10-129
work_keys_str_mv AT ummanniramesh ubiquitincarboxylterminalhydrolase1uchl1isapotentialtumoursuppressorinprostatecancerandisfrequentlysilencedbypromotermethylation
AT jostedgar ubiquitincarboxylterminalhydrolase1uchl1isapotentialtumoursuppressorinprostatecancerandisfrequentlysilencedbypromotermethylation
AT braigmelanie ubiquitincarboxylterminalhydrolase1uchl1isapotentialtumoursuppressorinprostatecancerandisfrequentlysilencedbypromotermethylation
AT lohmannfrithjof ubiquitincarboxylterminalhydrolase1uchl1isapotentialtumoursuppressorinprostatecancerandisfrequentlysilencedbypromotermethylation
AT mundtfrederike ubiquitincarboxylterminalhydrolase1uchl1isapotentialtumoursuppressorinprostatecancerandisfrequentlysilencedbypromotermethylation
AT barettchristine ubiquitincarboxylterminalhydrolase1uchl1isapotentialtumoursuppressorinprostatecancerandisfrequentlysilencedbypromotermethylation
AT schlommthorsten ubiquitincarboxylterminalhydrolase1uchl1isapotentialtumoursuppressorinprostatecancerandisfrequentlysilencedbypromotermethylation
AT sauterguido ubiquitincarboxylterminalhydrolase1uchl1isapotentialtumoursuppressorinprostatecancerandisfrequentlysilencedbypromotermethylation
AT senfftina ubiquitincarboxylterminalhydrolase1uchl1isapotentialtumoursuppressorinprostatecancerandisfrequentlysilencedbypromotermethylation
AT bokemeyercarsten ubiquitincarboxylterminalhydrolase1uchl1isapotentialtumoursuppressorinprostatecancerandisfrequentlysilencedbypromotermethylation
AT sultmannholger ubiquitincarboxylterminalhydrolase1uchl1isapotentialtumoursuppressorinprostatecancerandisfrequentlysilencedbypromotermethylation
AT meyerschwesingercatherine ubiquitincarboxylterminalhydrolase1uchl1isapotentialtumoursuppressorinprostatecancerandisfrequentlysilencedbypromotermethylation
AT brummendorftimh ubiquitincarboxylterminalhydrolase1uchl1isapotentialtumoursuppressorinprostatecancerandisfrequentlysilencedbypromotermethylation
AT balabanovstefan ubiquitincarboxylterminalhydrolase1uchl1isapotentialtumoursuppressorinprostatecancerandisfrequentlysilencedbypromotermethylation